Search results for "lung cancer"
showing 10 items of 508 documents
Cancer prevalence is increased in females with sleep apnoea: data from the ESADA study
2019
[No abstract available]
Characterization of materials toward toluene traces detection for air quality monitoring and lung cancer diagnosis
2017
International audience; The aim of this work was to identify a nanoporous material able to trap toluene traces in order to develop a gas detection device for indoor air quality monitoring or biomedical diagnosis. A set of various adsorbents such as zeolites and activated carbon microspheres was studied here. First a detailed characterization of their porous properties was performed by nitrogen adsorption. Then adsorption of toluene and other interfering compounds which can selectively adsorbed with it, such as water and carbon dioxide, was studied in order to select the most suitable material. Results revealed that the activatedcarbon microspheres W5 and the zeolite NaY, which exhibit high …
Detection and quantification of lung cancer biomarkers by a micro-analytical device using a single metal oxide-based gas sensor
2018
International audience; The analysis of exhaled volatile organic compounds (VOCs) related to lung cancer is a very promising wayin medical diagnosis because it is non-invasive and much less expensive than traditional medical analysisused so far. In that sense, a silicon micro-analytical platform consisting of a micro-preconcentrator cou-pled to a silicon spiral gas chromatographic micro-column was built, and a metal oxide-based gas sensorwas used as a miniaturized gas detector. This micro-fabricated device was successfully tested to selec-tively detect low concentrations of VOCs considered as lung cancer biomarkers, within a few minuteseven in presence of high concentrations of water vapor …
Plasmonic Biosensors for the Detection of Lung Cancer Biomarkers: A Review
2021
Lung cancer is the most common and deadliest cancer type globally. Its early diagnosis can guarantee a five-year survival rate. Unfortunately, application of the available diagnosis methods such as computed tomography, chest radiograph, magnetic resonance imaging (MRI), ultrasound, low-dose CT scan, bone scans, positron emission tomography (PET), and biopsy is hindered due to one or more problems, such as phenotypic properties of tumours that prevent early detection, invasiveness, expensiveness, and time consumption. Detection of lung cancer biomarkers using a biosensor is reported to solve the problems. Among biosensors, optical biosensors attract greater attention due to being ultra-sensi…
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatme…
2016
NSC12 is an orally available pan-FGF trap able to inhibit FGF2/FGFR interaction and endowed with promising antitumor activity. It was identified by virtual screening from a NCI small molecule library, but no data were available about its synthesis, stereochemistry, and physicochemical properties. We report here a synthetic route that allowed us to characterize and unambiguously identify the structure of the active compound by a combination of NMR spectroscopy and in silico conformational analysis. The synthetic protocol allowed us to sustain experiments aimed at assessing its therapeutic potential for the treatment of FGF-dependent lung cancers. A crucial step in the synthesis generated a c…
IMMUNO-ONCOLOGICAL TREATMENT OF NON-SMALL-CELL LUNG CANCER IN ADVANCED STAGE WITH NIVOLUMAB
2021
In recent years, significant scientific progress has been made in the therapy of non-small cell lung cancer (NSCLC),which has made possible a better knowledge of this pathology and above all the realization of new personalized therapies. The main therapeutic revolution in advanced NSCLC is immunooncology, a new therapeutic strategy that aims to awaken the immune system to fight cancer cells. Our work helped us evaluate the therapeutic efficacy of monotherapy with Nivolumab in the treatment of patients with advanced stage IIIB/IV non-smallcell lung cancer beyond the second line. We can conclude that in the treatment of non-small-cell lung cancer, the use of Nivolumab improves the prognosis a…
Erratum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases (Scientific Reports (2015) 5 (18670) DOI: 10.1038/srep18670)
2016
Erratum for Natural History of Non-Small-Cell Lung Cancer with Bone Metastases
Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population-based cohort
2022
Background: Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scarce. This study assessed the risk of subsequent malignant neoplasms (SMNs) to identify the most common SMNs to be considered in follow-up care. Methods: Population-based cancer registries retrospectively identified first primary tumors (between 1976 and 2013) and SMNs in AYAs (15-39 years old at their cancer diagnosis). AYA cancer survivors were those alive at least 5 years after their first cancer diagnosis. The excess risk of SMNs was measured as standardized incidence ratios (SIRs) and absolute excess risk together with the cumulative incidence of SMNs. Results: The cohort included 67,692 A…
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer p…
2011
Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial- growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the anti-angiogenic effects and toxicity of a newest bevacizumab-based combination with fractioned cisplatin and daily oral etoposide. We designed a phase II trial to evaluate in advanced NSCLC patients the antitumor activity and the safety of this novel regimen. In particular, 45 patients (36 males and 9 females), with a mean age of 54 years, an ECOG ≤2, stage III B/IV and NSCLC (28 adenocarcinomas, 11 squamous-cell carcinomas, 2 large-cell carcin…
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy
2010
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 119…